LJ501-CRH01: A phase 3, placebo-controlled, randomized, double-blind, multi-center study of LJPC-501 in patients with catecholamine-resistant hypotension (CRH),
Role: Investigator,
La Jolla Pharmaceutical Company,
(02/2017 - 02/2018)
Status: Completed
A sample collection study to validate the astute medical NephroCheck test in critically ill subjects at risk for acute kidney injury,
Role: Investigator,
Astute Medical, Inc,
(06/2012 - 06/2013)
Status: Completed
OASIS: A phase 2/3 randomized, double-blind, placebo-controlled, study of the safety and efficacy of talactoferrin alfa in patients with severe sepsis,
Role: Investigator,
Agennix, Inc.,
(05/2012 - 05/2013)
Status: Completed
Efficacy and safety of drotrecogin alfa (activated) in adult patients with septic shock,
Role: Investigator,
Eli Lilly & Co.,
(09/2011 - 09/2012)
Status: Completed
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin alfa in patients with severe sepsis, protocol LF-0801,
Role: Investigator,
Agennix, Inc.,
(03/2009 - 03/2010)
Status: Completed
A phase 2 study to evaluate dose and duration of treatment of drotrecogin alfa (activated) using serial measurements of protein C in patients with severe and multiple organ dysfunctions,
Role: Investigator,
Eli Lilly & Co.,
(11/2008 - 11/2009)
Status: Completed
A prospective, randomized, double-blind, placebo controlled, dose ranging, multi-center study of the safety and efficacy of three days continuous intravenous infusion of GR270773 in the treatment of suspected or confirmed gram-negative severe sepsis in adults,
Role: Investigator,
GlaxoSmithKline,
(07/2005 - 07/2006)
Status: Completed
A randomized, double-blind, placebo-controlled trial of prophylactic heparin in patients with severe sepsis and higher disease severity who are undergoing treatment with Drotrecogin Alfa (activated),
Role: Investigator,
Eli Lilly & Co.,
(12/2004 - 12/2005)
Status: Completed
Multicenter study to evaluate the safety and efficacy of levofloxacin 500 mg., once daily, in treatment of community-acquired pneumonia in adults (CAPSS-043),
Role: PI,
Ortho-McNeil Pharmaceutical,
(10/1999 - 10/2000)
Status: Completed
A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging evaluation of the safety and efficacy of a-hANP infusion (Carperitide for injection: SUN 4936) in patients with acute respiratory distress syndrome (ARDS) - Amendment 5.,
Role: Investigator,
Suntory Pharmaceuticals, Inc.,
Status: Completed
Internal
Fractional exhaled Nitric Oxide (FeNO) levels pre and post Hyperbaric oxygen therapy,
Role: Investigator,
LLU Dept. of Medicine,
(03/2019 - 03/2020)
Status: Completed
Antibiotic prophylaxis in hospitalized patients with end stage liver disease (model for end stage liver disease score >30),
Role: PI,
LLU Dept. of Medicine,
(11/2014 - 11/2015)
Status: Completed
Hyperbaric oxygen therapy in critically ill patients: a retrospective chart review,
Role: PI,
LLU Dept. of Medicine,
(07/2014 - 07/2015)
Status: Completed
Fluctuations in blood glucose levels during hyperbaric oxygen therapy,
Role: PI,
LLUMC - Respiratory Care,
(07/2014 - 07/2015)
Status: Completed
Perceptions of the appropriateness of care among intensive care nurses and physicians in California,
Role: Investigator,
LLU Dept. of Nursing - Graduate,
(05/2013)
Status: Completed
The relative yield of bronchial washings versus bronchial lavage for various micro-organisms,
Role: PI,
LLU Dept. of Medicine,
(03/2012 - 03/2013)
Status: Completed
An observational study - timing of hospital discharge after antibiotics are changed from intravenous to oral; same day versus next day. A risk benefit analysis.,
Role: PI,
Loma Linda University Medical Center,
(06/1999 - 05/2000)
Status: Completed
A double blind, randomized, placebo controlled study of inhaled nitric oxide in the treatment of Acute Respiratory Distress Syndrome (ARDS),
Role: Investigator,
LLU Dept. of Medicine,
(12/1998 - 12/1999)
Status: Completed
International study of mechanical ventilation,
Role: Investigator,
Loma Linda University Medical Center,
(02/1998)
Status: Completed
LLU Cancer Center biospecimen laboratory - specimens collection protocol,
Role: Investigator,
LLU Cancer Institute,
(09/2024 - 09/2025)
Status: Approved